Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer
Autore:
Gil-Delgado, MA; Guinet, F; Castaing, D; Adam, R; Coeffic, D; Durrani, AKS; Bismuth, H; Khayat, D;
Indirizzi:
Hop La Pitie Salpetriere, Dept Med Oncol, F-75013 Paris, France Hop La Pitie Salpetriere Paris France F-75013 col, F-75013 Paris, France Hop Paul Brousse, Ctr Hepatobiliaire, Villejuif, France Hop Paul Brousse Villejuif France Ctr Hepatobiliaire, Villejuif, France
Titolo Testata:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
fascicolo: 1, volume: 24, anno: 2001,
pagine: 101 - 105
SICI:
0277-3732(200102)24:1<101:PPITOI>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE LEUCOVORIN; EVERY 2 WEEKS; CONTINUOUS-INFUSION; CAMPTOTHECIN; FLUOROURACIL; CHEMOTHERAPY; REGIMEN; CPT-11; BOLUS; LV5FU2;
Keywords:
advanced colorectal cancer; combination chemotherapy; phase II trials; irinotecan; 5-fluorouracil; folinic acid;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Gil-Delgado, MA Hop La Pitie Salpetriere, Dept Med Oncol, 47 Blvd Hop, F-75013 Paris, France Hop La Pitie Salpetriere 47 Blvd Hop Paris France F-75013
Citazione:
M.A. Gil-Delgado et al., "Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer", AM J CL ONC, 24(1), 2001, pp. 101-105

Abstract

Irinotecan (CPT11) has established activity in the treatment of advanced colorectal cancer without cross-resistance with established 5-fluorouracil/folinic acid-based therapy. This phase II study was conducted to establish the efficacy and tolerance of combination treatment with irinotecan and 5-fluorouracil as salvage treatment for this disease. Open phase II trial of CPT Ii 180 mg/m(2) on day 1, leucovorin 200 mg/m(2) on days 1 and 2, and 5-fluorouracil 400 mg/m(2) loading dose followed by 600 mg/m(2) infusion on days 1 and 2. Treatment was continued until progression or limiting toxicity. Responders could proceed to surgical resection of residual disease. Thirty-nine patients from 2 institutions received a total of 287 cycles of therapy(median 7 cycles/patient). Eight patients achieved an objective response (7 for liver metastasis and 1 for lung metastasis), and an additional 12 obtained stabilization of disease or minor responses (MR): of these patients, 8 with liver metastasis (7 partial response and 1 MR) underwent hepatic resection of metastases and all them obtained a complete response. The median duration of response was 14 months, and the median survival was 11 months. Hematologic toxicity (neutropenia) was the most common serious side effect (29% of patients in 2% of cycles), but significant fever developed in only 4 patients. Grade III diarrhea was experienced in at least 1 cycle by 10% of patients. The results of this schedule compare favorably with previously reported experience of a phase I study designed to establish the dose of CPT11. Efficacy in this poor prognosis group of patients is very encouraging,and the schedule is well tolerated by even previously treated patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:11:50